Erythropoietin in Kidney Disease and Type 2 Diabetes

被引：0
|
作者：
Thum, Thomas [1 ]
Kalantar-Zadeh, Kamyar [2 ]
Anker, Stefan D. [3 ]
机构：
[1] Hannover Med Sch, D-3000 Hannover, Germany
[2] Harbor UCLA Med Ctr, Torrance, CA 90509 USA
[3] Charite Campus Virchow Klinikum, Berlin, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 364卷 / 04期
关键词：
IRON-DEFICIENCY;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：384 / 385
页数：3
相关论文
共 50 条
  • [1] Association of circulating autoantibodies to erythropoietin receptor with anaemia in patients with type 2 diabetes and chronic kidney disease
    Oshima, Megumi
    Toyama, Tadashi
    Ito, Kiyoaki
    Kitajima, Shinji
    Mizushima, Ichiro
    Hara, Akinori
    Sakai, Norihiko
    Shimizu, Miho
    Wada, Takashi
    Iwata, Yasunori
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2740 - I2740
  • [2] Association of circulating autoantibodies to erythropoietin receptor with anaemia in patients with type 2 diabetes and chronic kidney disease
    Oshima, Megumi
    Toyama, Tadashi
    Ito, Kiyoaki
    Kitajima, Shinji
    Mizushima, Ichiro
    Hara, Akinori
    Sakai, Norihiko
    Shimizu, Miho
    Wada, Takashi
    Iwata, Yasunori
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [3] Dulaglutide slows kidney disease in type 2 diabetes
    Oliva-Damaso, Nestor
    Oliva-Damaso, Elena
    Payan, Juan
    Porrini, Esteban
    LANCET, 2020, 395 (10224): : 559 - 559
  • [4] Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
    Wanner, Christoph
    Inzucchi, Silvio E.
    Lachin, John M.
    Fitchett, David
    von Eynatten, Maximilian
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Zinman, Bernard
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 323 - 334
  • [5] Semaglutide for Chronic Kidney Disease in Type 2 Diabetes
    Passos, Rogerio da Hora
    Narciso, Roberto Camargo
    da Silva, Arnaldo Alves
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (18): : 1757 - 1757
  • [6] Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
    Pareek, Anil
    Chandurkar, Nitin
    Naidu, Kumar
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1800 - 1800
  • [7] Management of type 2 diabetes in chronic kidney disease
    Triozzi, Jefferson L.
    Parker Gregg, L.
    Virani, Salim S.
    Navaneethan, Sankar D.
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [8] The Genetic Risk of Kidney Disease in Type 2 Diabetes
    Pezzolesi, Marcus G.
    Krolewski, Andrzej S.
    MEDICAL CLINICS OF NORTH AMERICA, 2013, 97 (01) : 91 - +
  • [9] Chronic kidney disease and peripheral artery disease in type 2 diabetes
    Chu, Chih-Hsun
    Sun, Chun-Chin
    Chuang, Wan-Chi
    Chang, Wei-Cheng
    Tsai, Yu-Hsuan
    Kao, Wang-Jung
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S68 - S69
  • [10] Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes
    Popovic, Djordje S.
    Patoulias, Dimitrios
    Gnudi, Luigi
    Mantzoros, Christos S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 151
12345